Get the Stockscreener App
11.35
8.51%
0.89
After Hours:
11.70
0.35
+3.08%
Delcath Systems Inc stock is traded at $11.35, with a volume of 848.20K.
It is up +8.51% in the last 24 hours and up +4.70% over the past month.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$10.46
Open:
$10.79
24h Volume:
848.20K
Relative Volume:
1.20
Market Cap:
$397.04M
Revenue:
$2.07M
Net Income/Loss:
$-47.68M
P/E Ratio:
-4.0248
EPS:
-2.82
Net Cash Flow:
$-31.31M
1W Performance:
+5.09%
1M Performance:
+4.70%
6M Performance:
+6.47%
1Y Performance:
+36.34%
1-Day Range:
$10.56
$11.45
1-Week Range:
$10.46
$11.45
52-Week Range:
$8.35
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
11.35 | 365.90M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
131.38 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
94.95 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.92 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.58 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.95 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
Can technical indicators confirm Delcath Systems Inc.’s reversalJuly 2025 EndofMonth & Safe Entry Trade Reports - newser.com
Evaluating Delcath Systems Inc. with trendline analysisJuly 2025 Selloffs & Technical Entry and Exit Alerts - newser.com
What candlestick patterns are forming on Delcath Systems Inc.CEO Change & AI Driven Price Predictions - newser.com
Momentum divergence signals in Delcath Systems Inc. chart2025 Momentum Check & Low Risk High Win Rate Picks - newser.com
Is it time to cut losses on Delcath Systems Inc.Quarterly Trade Summary & Fast Entry High Yield Tips - newser.com
How to use a screener to detect Delcath Systems Inc. breakoutsWeekly Trend Report & Intraday High Probability Setup Alerts - newser.com
What to expect from Delcath Systems Inc. in the next 30 daysAnalyst Upgrade & Daily Stock Trend Reports - newser.com
Tools to assess Delcath Systems Inc.’s risk profileWeekly Trend Summary & Long Hold Capital Preservation Tips - newser.com
Is Delcath Systems Inc a good long term investmentEconomic Data Impact & High Return Market Tips - earlytimes.in
What indicators show strength in Delcath Systems Inc.July 2025 Movers & Safe Capital Investment Plans - newser.com
Detecting price anomalies in Delcath Systems Inc. with AIWeekly Stock Analysis & Free Weekly Watchlist of Top Performers - newser.com
Using Python tools to backtest Delcath Systems Inc. strategiesTrade Risk Report & Detailed Earnings Play Alerts - newser.com
What Fibonacci levels say about Delcath Systems Inc. rebound2025 Valuation Update & High Yield Stock Recommendations - newser.com
How to forecast Delcath Systems Inc. trends using time seriesEarnings Recap Summary & Fast Entry Momentum Trade Alerts - newser.com
Delcath Systems (NASDAQ:DCTH) Given Hold (C-) Rating at Weiss Ratings - MarketBeat
Will Delcath Systems Inc. (DV3R) stock outperform Dow JonesWeekly Trade Recap & Breakout Confirmation Alerts - newser.com
Advanced analytics toolkit walkthrough for Delcath Systems Inc.Earnings Performance Report & Precise Swing Trade Entry Alerts - newser.com
Candlestick signals on Delcath Systems Inc. stock todayFed Meeting & Growth Focused Stock Pick Reports - newser.com
Why global investors buy Delcath Systems Inc. (DV3R) stock2025 Support & Resistance & Verified Chart Pattern Trade Signals - newser.com
What does recent volatility data suggest for Delcath Systems Inc.Market Risk Summary & Safe Entry Trade Signal Reports - newser.com
Delcath Systems (DCTH): Evaluating Valuation After CHOPIN Phase 2 Trial Results Announcement for Uveal Melanoma - Sahm
Delcath Systems Inc DV3R Stock Analysis and ForecastEconomic Data Impact & Use Smart Algorithms to Pick Better Stocks - earlytimes.in
Is Delcath Systems Inc. stock cheap at current valuationMarket Activity Report & Expert-Curated Trade Recommendations - newser.com
Pattern recognition hints at Delcath Systems Inc. upsideEarnings Growth Report & Free Expert Verified Stock Movement Alerts - newser.com
Published on: 2025-10-05 05:55:28 - newser.com
Why Delcath Systems Inc. (DV3R) stock stays undervaluedInsider Buying & Free Technical Pattern Based Buy Signals - newser.com
What MACD signals say about Delcath Systems Inc.Trade Ideas & Real-Time Price Movement Reports - newser.com
Wall Street Zen Upgrades Delcath Systems (NASDAQ:DCTH) to “Buy” - Defense World
Wall Street Zen Upgrades Delcath Systems (NASDAQ:DCTH) to "Buy" - MarketBeat
Delcath Systems, Inc. (NASDAQ:DCTH) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Biliary Tract Cancer Market Expected to Gain Momentum Through 2034, According to DelveInsight | AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharma, Eisai - Barchart.com
Biliary Tract Cancer Market Expected to Gain Momentum Through - openPR.com
Nkarta Inc Stock Analysis and ForecastPrice Support Zones & Exceptional Profit Trading - earlytimes.in
Delcath sets outlook amid plans to enter National Medicaid Drug Rebate Agreement - MSN
Delcath Systems Inc Stock Analysis and ForecastEarnings Growth Projections & Investment Risk Management Tips - earlytimes.in
United States Uveal Melanoma Treatment Market Set to Soar with - openPR.com
Is Delcath Systems Inc DV3R a good long term investmentHigh Yield Income Stocks & Your Roadmap to 10x Returns Starts Here - earlytimes.in
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Delcath Systems Inc Stock (DCTH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER |
Oct 22 '24 |
Option Exercise |
6.00 |
16,666 |
99,996 |
319,334 |
0.01%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):